Osteoarthritis Therapeutics Market Size, Share & Analysis Report, 2022-2030
According to Nova one advisor, the global Osteoarthritis Therapeutics market size is expected to hit around USD 21.0 billion by 2030 from valued at USD 9.3 billion in 2021 and growing at a CAGR of 11.7% from 2022 to 2030.
The increased geriatric population and increased number of drug approvals for the treatment of pain caused by osteoarthritis are two factors driving the global osteoarthritis therapeutics market.
Furthermore, the rising prevalence of osteoarthritis, such as knee and hip osteoarthritis, contributes significantly to the osteoarthritis therapeutics market growth.
Report Scope of the Osteoarthritis Therapeutics Market
|
Report Coverage |
Details |
|
Market Size |
USD 21.0 Billion by 2030 |
|
Growth Rate |
CAGR of 11.7% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Anatomy, drug type, route of administration, prescription pattern, distribution channeland Region, |
|
Companies Mentioned |
Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain) |
TRENDS INFLUENCING THE GROWTH OF OSTEOARTHRITIS THERAPEUTICS MARKET
An increase in the geriatric population is expected to drive the growth of the Osteoarthritis Therapeutics market. Osteoarthritis is the most common type of arthritis in older people, and it is also one of the leading causes of physical disability. Both men and women are affected by the disease. The hands, lower back, neck, and weight-bearing joints such as knees, hips, and feet are the most common sites of osteoarthritis. Only the joints are affected by osteoarthritis, not the internal organs. Osteoarthritis is more likely to develop as you get older. Excess weight, improper joint alignment, and putting too much stress on a previously injured joint can all contribute to the development of osteoarthritis.
The rising prevalence of osteoarthritis, such as knee and hip osteoarthritis, is expected to boost the market for osteoarthritis therapeutics. The breakdown of joint tissues from mechanical loading and inflammation is thought to be the proximate cause of knee Osteoarthritis, but the deeper underlying causes of the disease's high prevalence are unknown and poorly tested, hampering efforts to prevent and treat it. However, two recent public health trends are widely assumed to be the most important. First, because the prevalence of knee OA rises with age, and second, because of a high BMI (BMI). Hip osteoarthritis causes stiffness and pain. It can make simple tasks difficult, such as bending over to tie a shoe, rising from a chair, or going for a short walk.
The rise in demand for cell-based research for Osteoarthritis is expected to further fuel the Osteoarthritis Therapeutics market. The development of stem cell-based OA therapies is at a crossroads. The extensive literature on stem cell isolation, chondrogenic differentiation, and scaffold design has enabled researchers and clinicians to consider the possibility of using stem cells to modify OA progression and tissue engineering to resurface an entire osteoarthritic joint surface, preventing or delaying the need for total joint replacement.
Market Dynamics
DRIVER: Rising government investments in cell-based research significant adoption of pain medications
Topical, oral, and parenteral pain medications are widely used to manage pain associated with osteoarthritis. Although alternatives such as orthopedic braces are used as part of a noninvasive approach for pain management, the adoption of pain medications for the condition is high owing to the ease of administration and the affordability of pain medications. Pain relievers such as oral analgesics (acetaminophen and NSAIDs such as ibuprofen, naproxen, tramadol, opiates, and duloxetine), topical agents (such as capsaicin and topical NSAIDs), intra-articular agents (such as corticosteroids and hyaluronic acid), and nutraceuticals (glucosamine and chondroitin) are widely used. Studies reveal that these medications offer a 30% reduction of chronic pain on administration.
The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period.
RESTRAINTS:Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
OTC and prescription NSAIDs are widely used to relieve pain in osteoarthritis patients. As per a study published by the National Center for Biotechnology Information in 2019, more than 50% of osteoarthritis patients in the US are prescribed NSAIDs. Similarly, in Europe, of the total number of osteoarthritis patients using prescription medications (47%), 60% received NSAIDs.
The use of NSAIDs is associated with an increased risk of adverse cardiovascular events. Both cyclooxygenase (COX)-2 selective NSAIDs (coxibs) and non-selective NSAIDs increase CVD risk in patients. A study presented at the Annual European Congress of Rheumatology (EULAR 2018) stated that more than two-thirds of the increased cardiovascular risk associated with osteoarthritis is linked to NSAIDs. Such risks associated with the use of NSAIDs can potentially discourage doctors from prescribing these medications while driving patients using OTC NSAIDs to opt for alternative products.
OPPORTUNITY: Personalized medicine for osteoarthritis
Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement, acceptable levels of sensitivity and specificity, and test methods that are accessible and interpretable by clinicians. The use of biomarkers to identify patients who are likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposure to therapies that are unlikely to be effective or expose patients to serious treatment-related side-effects. The combination of unique biomarkers and baseline clinical characteristics such as sex and age may further enhance efforts to personalize treatment regimens for RA.
“Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2021.”
Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.
“Viscosupplementation agents is expected to hold the largest share of the osteoarthritis therapeutics market, in 2021.”
Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmented into naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2020. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Viscosupplementation effectively eases the pain of osteoarthritis through injections that fill up the joint’s synovial fluid, thus offering better lubrication of the joints.
“Parental route is expected to hold the largest share of the osteoarthritis therapeutics market in 2021.”
On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes. The parenteral route accounted for the largest share of this market in 2020 and is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the wide adoption of the parenteral route for administering osteoarthritis therapeutics owing to the ease of administration and the better pharmacokinetics and pharmacodynamics, resulting in better patient compliance.
“Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2021.”
Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. In 2020, hospital pharmacies accounted for the largest share of this market because of the high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies. Reimbursements can also be claimed easily on hospital pharmacy purchases, which is another important draw.
“Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2021.”
Based on the purchasing pattern, the osteoarthritis therapeutics market is segmented into OTC and prescription drugs. In 2020, the prescription drugs segment accounted for a larger share of this market as most osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are only available on prescription.
“Europe commanded the largest share of the osteoarthritis therapeutics market in 2021.”
On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2020, Europe commanded the largest share of the osteoarthritis therapeutics market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents.
Some of the prominent players in the Osteoarthritis Therapeutics Market include:
Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Osteoarthritis Therapeutics market
Osteoarthritis Therapeutics by Anatomy
Osteoarthritis Therapeutics by Drug Type
Osteoarthritis Therapeutics by Route of Administration
Osteoarthritis Therapeutics by Purchasing Pattern
Osteoarthritis Therapeutics Market, by Distribution Channel
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 31)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 LIMITATIONS OF THE CURRENT EDITION
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.2.3 TOP-DOWN APPROACH
FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020 VS. 2030 (USD BILLION) 43
FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020 VS. 2030 (USD BILLION) 44
FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2030 (USD BILLION)
FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020 VS. 2030 (USD BILLION)
FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2020 VS. 2030 (USD BILLION) 46
FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2020 VS. 2030 (USD BILLION) 47
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
FIGURE 13 INCREASING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY DRUG TYPE (2019)
FIGURE 14 VISCOSUPPLEMENTATION AGENTS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2020
4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET
FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD IN THE OSTEOARTHRITIS THERAPEUTICS MARKET 50
5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Significant adoption of pain medications
5.2.1.2 Increasing prevalence of osteoarthritis
5.2.1.3 Growing population susceptible to osteoarthritis
FIGURE 17 SHARE OF OBESE ADULTS, BY REGION (2016)
5.2.1.4 Rising number of sports injuries
FIGURE 18 INJURIES CAUSED BY SPORTS ACTIVITIES IN THE US (2019)
5.2.2 RESTRAINTS
5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment
5.2.2.2 Commercialization of alternatives
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicines for osteoarthritis
5.2.3.2 Emerging markets
5.2.3.3 Collaborations for product development
5.2.4 CHALLENGES
5.2.4.1 Adoption of non-drug pain management therapies
5.3 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS: PHARMACEUTICALS INDUSTRY
TABLE 1 COSTS INCURRED AND VALUE ADDED ACROSS THE VALUE CHAIN, BY COMPONENT
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 20 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 21 ECOSYSTEM ANALYSIS
5.6 COVID-19 IMPACT ANALYSIS ON THE OSTEOARTHRITIS THERAPEUTICS MARKET
5.7 AVERAGE SELLING PRICE TREND
TABLE 2 AVERAGE SELLING PRICE OF OSTEOARTHRITIS DRUGS
5.8 REGULATORY SCENARIO
TABLE 3 LIST OF REGULATORY AUTHORITIES IN THE PHARMA INDUSTRY
5.8.1 REGULATORY REQUIREMENTS
5.8.1.1 EU regulations
5.8.1.2 US regulations
5.9 EPIDEMIOLOGY (PATIENT POPULATION)
5.9.1 SEVERITY
TABLE 4 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY SEVERITY (2019)
5.9.2 ANATOMY
TABLE 5 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY ANATOMY (2019)
6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY (Page No. - 67)
6.1 INTRODUCTION
TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
6.2 KNEE OSTEOARTHRITIS
6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
TABLE 7 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
6.3 HIP OSTEOARTHRITIS
6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
TABLE 8 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
6.4 HAND OSTEOARTHRITIS
6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
TABLE 9 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
6.5 SMALL JOINT OSTEOARTHRITIS
6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS
TABLE 10 SMALL JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE (Page No. - 72)
7.1 INTRODUCTION
TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
7.2 VISCOSUPPLEMENTATION AGENTS
7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2019
TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2022-2030 (USD MILLION)
7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE ADVERSE EFFECTS OF CORTICOSTEROIDS
TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2022-2030 (USD MILLION)
7.3.1.1 Ibuprofen
TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2022-2030 (USD MILLION)
7.3.1.2 Aspirin
TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION, 2022-2030 (USD MILLION)
7.3.1.3 Diclofenac
TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2022-2030 (USD MILLION)
7.3.1.4 Naproxen
TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2022-2030 (USD MILLION)
7.3.1.5 Other NSAIDs
TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER NSAIDS, BY REGION, 2022-2030 (USD MILLION)
7.4 ANALGESICS
7.4.1 ACETAMINOPHEN HOLDS THE LARGEST SHARE OF THE ANALGESICS MARKET
TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2022-2030 (USD MILLION)
7.4.1.1 Acetaminophen
TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2022-2030 (USD MILLION)
7.4.1.2 Duloxetine
TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2022-2030 (USD MILLION)
7.5 CORTICOSTEROIDS
7.5.1 EUROPE AND NORTH AMERICA ARE THE LARGEST MARKETS FOR CORTICOSTEROIDS
TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2030 (USD MILLION)
8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 81)
8.1 INTRODUCTION
TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
8.2 PARENTERAL ROUTE
8.2.1 DRUGS INEFFECTIVE WHEN ADMINISTERED ORALLY CAN BE DELIVERED VIA PARENTERAL ROUTE
TABLE 26 PARENTERAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
8.3 ORAL ROUTE
8.3.1 ORAL ROUTE IS WIDELY PREFERRED BY BOTH CLINICIANS AND PATIENTS
TABLE 27 ORAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
8.4 TOPICAL ROUTE
8.4.1 EASE OF USE, PAINLESS AND NON-INVASIVE ADMINISTRATION HAVE SUPPORTED USE OF TOPICAL ROUTE
TABLE 28 TOPICAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL (Page No. - 85)
9.1 INTRODUCTION
TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
9.2 HOSPITAL PHARMACIES
9.2.1 HOSPITAL PHARMACIES ARE THE LARGEST DISTRIBUTION CHANNEL FOR OSTEOARTHRITIS THERAPEUTICS
TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2030 (USD MILLION)
9.3 RETAIL PHARMACIES
9.3.1 GREATER PREFERENCE FOR RETAIL PHARMACIES HAS AFFECTED MARKET SHARE
TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2030 (USD MILLION)
9.4 ONLINE PHARMACIES
9.4.1 ONLINE PHARMACIES TO REGISTER THE HIGHEST GROWTH
TABLE 32 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2030 (USD MILLION)
10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN (Page No. - 89)
10.1 INTRODUCTION
TABLE 33 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
10.2 PRESCRIPTION DRUGS
10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
TABLE 34 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2030 (USD MILLION)
10.3 OVER-THE-COUNTER DRUGS
10.3.1 EASE OF PURCHASE AND ADMINISTRATION ARE RESULTING IN A RISING DEMAND FOR OTC DRUGS
TABLE 35 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2030 (USD MILLION)
11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION (Page No. - 92)
11.1 INTRODUCTION
TABLE 36 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
11.2 EUROPE
FIGURE 22 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 40 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 41 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 42 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 43 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 44 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.1 ITALY
11.2.1.1 Italy dominates the European market for osteoarthritis therapeutics
TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 47 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 48 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 49 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 50 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 51 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.2 GERMANY
11.2.2.1 Road accidents in the country to propel the demand for osteoarthritis therapeutics
TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 54 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 55 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 56 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 57 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 58 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.3 SPAIN
11.2.3.1 High prevalence of osteoarthritis to drive the growth of the market
TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 61 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 62 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 63 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 64 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 65 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.4 FRANCE
11.2.4.1 Rising geriatric population to accelerate the growth of the market during the forecast period
TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 68 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 69 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 70 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 71 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 72 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.5 UK
11.2.5.1 Increasing obesity rate and rising incidence of musculoskeletal diseases drive the market in the UK
TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 75 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 76 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 77 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 78 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 79 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.2.6 REST OF EUROPE
TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 82 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 83 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 84 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 85 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 86 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.3 NORTH AMERICA
TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 90 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 91 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 92 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 93 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 94 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.3.1 US
11.3.1.1 The US holds the largest share in the North American market
TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 97 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 98 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 99 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 100 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 101 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.3.2 CANADA
11.3.2.1 Rising geriatric and obese populations will drive the incidence of osteoarthritis therapeutics
TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 104 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 105 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 106 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 107 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 108 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 23 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 112 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 113 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 114 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 115 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 116 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Japan dominates the osteoarthritis therapeutics market in the APAC
TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 119 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 120 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 121 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 122 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 123 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Rising geriatric population to propel the demand for osteoarthritis therapeutics in China
TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 126 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 127 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 128 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 129 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 130 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Rising prevalence of osteoarthritis to accelerate market growth in India
TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 133 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 134 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 135 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 136 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 137 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Initiatives by market players to support the growth of the market
TABLE 138 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 139 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 140 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 141 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 142 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 143 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 144 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Prevalence of osteoarthritis to accelerate the growth of the market
TABLE 145 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 146 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 147 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 148 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 149 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 150 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 151 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 152 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 153 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 154 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 155 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 156 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 157 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 158 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 159 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
TABLE 160 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 161 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 162 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 163 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 164 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 165 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 166 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.5.1 LATIN AMERICA
11.5.1.1 Latin America holds a larger share of the RoW market
TABLE 167 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 168 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 169 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 170 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 171 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 172 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 173 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
11.5.2 MIDDLE EAST AND AFRICA
11.5.2.1 Rising obesity rates to propel market growth
TABLE 174 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2022-2030 (USD MILLION)
TABLE 175 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
TABLE 176 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2022-2030 (USD MILLION)
TABLE 177 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2022-2030 (USD MILLION)
TABLE 178 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 179 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 180 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2022-2030 (USD MILLION)
12 COMPETITIVE LANDSCAPE & COMPANY PROFILES (Page No. - 148)
12.1 COMPETITIVE LANDSCAPE
12.1.1 OVERVIEW
FIGURE 24 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET, JANUARY 2017-NOVEMBER 2020
FIGURE 25 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO NOVEMBER 2020
12.1.2 COMPETITIVE SCENARIO
12.1.2.1 Product launches and approvals
TABLE 181 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017?NOVEMBER 2020
12.1.2.2 Collaborations and agreements
TABLE 182 KEY COLLABORATIONS AND AGREEMENTS, JANUARY 2017?NOVEMBER 2020
12.1.2.3 Expansions
TABLE 183 KEY EXPANSIONS, JANUARY 2017?NOVEMBER 2020
12.1.2.4 Mergers and acquisitions
TABLE 184 KEY MERGERS AND ACQUISITIONS, JANUARY 2017?NOVEMBER 2020
12.1.2.5 Other developments
TABLE 185 OTHER DEVELOPMENTS, JANUARY 2017?NOVEMBER 2020
12.1.3 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
FIGURE 26 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019
12.1.4 COMPANY EVALUATION MATRIX
12.1.4.1 Stars
12.1.4.2 Emerging leaders
12.1.4.3 Pervasive companies
12.1.4.4 Participants
FIGURE 27 OSTEOARTHRITIS THERAPEUTICS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2019
12.2 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, SWOT analysis, MNM view)*
12.2.1 PFIZER, INC.
FIGURE 28 PFIZER, INC.: COMPANY SNAPSHOT (2019)
12.2.2 HORIZON THERAPEUTICS PLC
FIGURE 29 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2019)
12.2.3 SANOFI
FIGURE 30 SANOFI: COMPANY SNAPSHOT (2019)
12.2.4 JOHNSON & JOHNSON
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
12.2.5 BAYER AG
FIGURE 32 BAYER AG: COMPANY SNAPSHOT (2019)
12.2.6 ABBOTT
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019)
12.2.7 GLAXOSMITHKLINE PLC
FIGURE 34 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
12.2.8 ZIMMER BIOMET HOLDINGS
FIGURE 35 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
12.2.9 NOVARTIS AG
FIGURE 36 NOVARTIS: COMPANY SNAPSHOT (2019)
12.2.10 FLEXION THERAPEUTICS, INC.
FIGURE 37 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2019)
12.2.11 ANIKA THERAPEUTICS
FIGURE 38 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2019)
12.2.12 ELI LILLY
FIGURE 39 ELI LILLY: COMPANY SNAPSHOT (2019)
12.2.13 HANMI PHARM. CO., LTD.
FIGURE 40 HANMI PHARM.CO., LTD.: COMPANY SNAPSHOT (2019)
12.2.14 ASSERTIO THERAPEUTICS, INC.
FIGURE 41 ASSERTIO THERAPEUTICS: COMPANY SNAPSHOT (2019)
12.2.15 LABORATORIO REIG JOFRE
FIGURE 42 LABORATORIO REIG JOFRE: COMPANY SNAPSHOT (2019)
12.2.16 KITOV PHARMACEUTICALS
FIGURE 43 KITOV PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2019)
12.2.17 VIRCHOW BIOTECH
12.2.18 FERRING PHARMACEUTICALS
12.2.19 BIOVENTUS
12.2.20 ALMATICA PHARMA LLC
12.2.21 ATNAHS
12.2.22 PHARMED LIMITED
12.2.23 ORTHOGENRX
12.2.24 LABRHA
12.2.25 FIDIA FARMACEUTICI S.P.A.
*Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 192)
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers